[144] Cellebrite DI Ltd. Warrants SEC Filing
Form 144 notice for CLBTW reports a proposed sale of 44,623 common shares with an aggregate market value of $722,768.43. The sale is noted as approximately on 08/27/2025 on NASDAQ. The filer documents acquisition details showing restricted stock grants on 02/14/2024 (22,003 shares), 05/14/2024 (5,497 shares) and 08/14/2025 (2,110 shares), plus a stock option exercise on 08/27/2025 for 15,013 shares paid in cash. The notice also lists two recent sales by the same person during the prior three months: 10,281 shares on 08/26/2025 for $164,651.09 and 37,965 shares on 08/25/2025 for $608,243.82. The filer attests there is no undisclosed material adverse information and follows Rule 144 disclosure requirements.
- None.
- None.
Insights
TL;DR: Insider sales totaling meaningful lot sizes disclosed; appears to be routine liquidity rather than operational signal.
The Form 144 shows a planned sale of 44,623 common shares (~$723k) and two recent sales totaling 48,246 shares (~$773k) executed within days. These dispositions largely stem from restricted stock vesting and an option exercise, with the exercise paid in cash, suggesting personal liquidity events rather than corporate financing. For investors, clustered insider sales can be noteworthy for timing and magnitude, but the filing provides no nonpublic operational information to imply company performance issues.
TL;DR: Disclosure is complete under Rule 144; signer affirms absence of undisclosed material facts and compliance with trading-plan representation.
The report includes acquisition provenance, payment method for the option exercise, and recent sales history, meeting key compliance standards. The attestation on material adverse information and note about trading plans addresses regulatory expectations. Governance-wise, the filing is transparent, but concentrated insider selling over a short period merits monitoring for patterns or announced personal trading plans.